SCHEMBL20153720

SCHEMBL20153720

CCOC(=O)/C=C/c1cncc(N2CCOCC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.45
AKT1 P31749 2/20 0.44
PIM2 Q9P1W9 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.39
DGAT1 O75907 1/20 0.39
SOAT1 P35610 1/20 0.39
POLB P06746 1/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 3/20 0.38
TSHR P16473 2/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALOX15 P16050 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20153727 0.78 ALDH1A1 (0.37) L3MBTL1KDM4EALDH1A1MAPTGAA
SCHEMBL20153785 0.78 MAPT (0.46) PIK3CAAKT1PIM2L3MBTL1ALDH1A1
SCHEMBL5867332 0.77 POLB (0.49) PIK3CAAKT1L3MBTL1KDM4EALDH1A1
SCHEMBL20153702 0.77 POLB (0.49) PIK3CAAKT1L3MBTL1KDM4EALDH1A1
SCHEMBL21564484 0.75 AKT1 (0.41) PIK3CAAKT1L3MBTL1KDM4EALDH1A1
SCHEMBL19304327 0.74 MAPT (0.61) L3MBTL1KDM4EALDH1A1MAPTLMNA
SCHEMBL20153810 0.73 CA12 (0.43) KDM4EALDH1A1MAPTGAANPC1
SCHEMBL21282928 0.71 HPGD (0.43) PIK3CAKDM4EALDH1A1POLBMAPT
SCHEMBL4773926 0.70 PIM2 (0.40) PIM2KDM4EALDH1A1POLBMAPT
SCHEMBL22734021 0.70 MAPT (0.44) L3MBTL1KDM4EALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538519-B1 INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2021-07-28 EP disclosed
US-11028071-B2 Indazole derivatives as alpha v integrin antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2021-06-08 US disclosed
US-20200339540-A1 INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2020-10-29 US disclosed
US-10745384-B2 Indazole derivatives as αv integrin antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-18 US disclosed
US-20190256496-A1 INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2019-08-22 US disclosed
WO-2018089357-A1 INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339540-A1 INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS ITGAV, ITGB1, ITGB3 PIK3CA 444/4885AKT1 520/4885PIM2 1584/4885
US-20190256496-A1 INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS ITGAV, ITGB1, ITGB3 PIK3CA 444/4885AKT1 520/4885PIM2 1584/4885
US-10745384-B2 Indazole derivatives as αv integrin antagonists ITGB3, ITGB1, ITGAV PIK3CA 702/4885AKT1 622/4885PIM2 1577/4885
US-11028071-B2 Indazole derivatives as alpha v integrin antagonists ITGAV, ITGB1, ITGB3 PIK3CA 444/4885AKT1 520/4885PIM2 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.